drugset / Trial / NCT06145360
Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
Phase 4
Completed
150 enrolled
SINA Health Education and Welfare Trust
Horizon Pharmaceutical Pvt Ltd · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
The primary aim of this study is to assess the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+Dipeptidyl peptidase 4 (DPP-4) inhibitors in poorly controlled type 2 diabetes mellitus (T2DM) patients. The study seeks to evaluate its effect on achieving glycemic goals in this patient population.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2024-03-01
- Completion
- 2024-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 10 mg | Oral |
| Comparator | Insulin | Protein / enzyme biologic | — | — |
| Comparator | Metformin | Small molecule | — | — |